6 best EDC platforms for decentralized clinical trials

A patient who drops out because travel to the clinic wasn't feasible costs you more than a single data point. It compounds across recruitment timelines, site activation costs, and the statistical power you budgeted for. Viedoc's eClinical platform delivers study builds in 2--4 weeks with integrated ePRO, Televisits, and real-time compliance monitoring across 7,000-plus completed studies in 75-plus countries, supporting decentralized and hybrid trial designs that prioritize patient retention without compromising data quality. This comparison evaluates six EDC platforms for decentralized clinical trials across patient engagement capability, remote monitoring tools, compliance infrastructure, and operational flexibility.

You're running trials where geographic distance, patient burden, and retention risk shape your protocol design as much as the science does. Decentralized and hybrid trials remove barriers to participation by bringing data collection to the patient rather than requiring them to travel to the site, but that shift demands technology that can handle remote visits, ePRO diaries, automated reminders, and real-time compliance tracking without introducing new operational friction for your study team.

Enterprise EDC platforms built for traditional site-based Phase III trials often treat decentralized capability as an add-on, not a core design principle. The result is fragmented workflows, manual reconciliation between ePRO and clinic data, and patient-facing tools that feel like afterthoughts. The platforms reviewed here are evaluated on their ability to support both remote and on-site visits within a single study, maintain data quality across distributed patient populations, and deliver the compliance credentials required for regulatory submissions.

Best EDC solutions for decentralized clinical trials

Platforms reviewed

These six eClinical platforms represent the most evaluated options for decentralized and hybrid clinical trials, reviewed across patient engagement tools, remote monitoring capability, data integration, and regulatory compliance.

1. Viedoc

Viedoc's eClinical platform combines EDC, ePRO, and Televisits in a unified system designed to eliminate the operational friction of managing remote and on-site visits in the same study. Viedoc's ePRO software captures patient-reported outcomes directly from participants' own devices with automated reminders and real-time compliance tracking, achieving 98% visit compliance rates in deployed studies. Viedoc's Televisits enable browser-based video interactions without app downloads, supporting encrypted peer-to-peer calls that meet HIPAA and GDPR requirements while allowing study teams to complete eCRFs and guide ePRO questionnaires during the call using picture-in-picture mode.

The platform's no-code Designer allows certified data managers to configure study workflows in-house without vendor-side programmers, a direct operational advantage for CROs and sponsors managing multiple concurrent decentralized studies. Viedoc supports 40-plus languages across 75-plus countries with 24/7 customer success, enabling global hybrid trial deployment with consistent patient experience across regions. Study builds are completed in 2--4 weeks, and the modular licensing model with unlimited user seats removes the per-user fee burden that penalizes remote site scale.

Viedoc's compliance infrastructure includes ISO 27001 and SOC 2 Type II certification, 21 CFR Part 11 compliant eSignature, EU Annex 11 and GDPR compliance, and HIPAA attestation for US protected health information handling. Hosted on Microsoft Azure with 99.99% uptime, the platform delivers enterprise-grade security and reliability for regulated commercial trials. Viedoc is used by CROs, growth-stage biotech sponsors, and MedTech companies running decentralized and hybrid studies across 7,000-plus completed trials globally.

"I am most impressed by the usability of the ePRO system and the extremely high compliance that we have been able to reach using the platform." Amanda M., Sr. Clinical Program Manager

Verified Proof Points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Visit compliance: 98% visit compliance rate with ePRO software
• Build speed: Study builds typically completed in 2--4 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Language support: Available in 40+ languages
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Support: 24/7 support across global offices
  

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Medidata

Medidata offers Rave EDC alongside a comprehensive eCOA platform designed for decentralized and hybrid clinical trials. The platform provides patient-facing tools for remote data collection, electronic consent, and symptom tracking, integrated with Medidata's broader clinical data ecosystem including safety monitoring and CTMS. Medidata's extensive validation library and regulatory track record make it a trusted choice for large pharma sponsors conducting complex Phase III decentralized trials. The platform supports advanced scripting and edit check configuration for sophisticated study designs, with established integrations across biostatistics and regulatory submission workflows.

3. Veeva Vault EDC

Veeva Vault EDC operates within the Vault Clinical suite, offering seamless integration across eTMF, CTMS, and safety management for sponsors seeking a unified platform. The cloud-native architecture delivers zero-downtime updates, allowing protocol amendments and system enhancements without disrupting active studies. Veeva's EDC supports hybrid trial designs with patient-facing data collection tools and compliance features including 21 CFR Part 11, GDPR, and ISO certifications. The platform is particularly strong with mid-to-large pharma sponsors already embedded in the Vault ecosystem, where cross-module integration delivers operational value for decentralized trial workflows.

4. Medable

Medable is a purpose-built decentralized clinical trial platform focused on patient engagement, eConsent, telehealth, and eCOA. The platform is designed to accelerate enrollment and improve retention by delivering best-in-class patient-facing interfaces for remote participation. Medable's strengths lie in its patient-centric design and enrollment acceleration capabilities, making it a strong fit for large pharma sponsors investing in fully decentralized or predominantly remote trial models. The platform is optimized for patient touchpoints rather than traditional site-based data management workflows.

5. Castor EDC

Castor EDC is a no-code, cloud-native EDC platform with API-first architecture supporting remote data collection and patient-facing tools. The platform includes integrated eConsent and ePRO modules designed for digital health studies, academic research, and hybrid clinical trials. Castor's intuitive interface and configurable workflows appeal to emerging biotech sponsors and CROs seeking flexibility without programmer dependency. The platform offers a free tier for academic trials, generating strong brand awareness in the research community, and is increasingly deployed in regulated commercial trials requiring decentralized capability.

6. Medrio

Medrio provides an EDC platform with ePRO, eConsent, and offline data capture capability, established in Phase I clinics, medical device trials, and remote site studies. The platform's offline functionality is valued for sites with intermittent connectivity, and its user-friendly interface supports rapid site activation for early-phase and device studies. Medrio operates in 100-plus countries with regulatory credibility across diverse markets, offering training programs and support infrastructure tailored to CROs managing distributed site networks. The platform is less prominent in late-phase commercial pharma but credible in its target segments of early-phase and device trials with remote monitoring requirements.

What to look for in EDC platforms for decentralized clinical trials

Integrated ePRO and remote visit capability

The defining requirement for decentralized trials is the ability to capture patient-reported outcomes and conduct remote visits without forcing your study team to reconcile data across multiple systems. Look for platforms where ePRO, Televisits, and clinic EDC share a unified database, eliminating manual data transfer and ensuring that remote and on-site visits appear in the same monitoring dashboards. Best-in-class platforms support automated reminders, compliance tracking, and real-time visibility into which patients are at risk of missing scheduled assessments. The operational test is whether your data managers can monitor both remote ePRO compliance and site visit completion from a single interface, rather than toggling between separate tools. Platforms that treat ePRO as a bolt-on module rather than a core component introduce reconciliation burden and increase the risk of protocol deviations when remote and clinic workflows diverge.

Patient engagement and retention tools

Patient dropout is the most expensive operational risk in decentralized trials, and your EDC platform directly influences retention rates through interface design, reminder infrastructure, and accessibility. Evaluate platforms on device flexibility — whether patients can complete assessments on smartphones, tablets, or web browsers without app downloads that create activation friction. Automated reminder systems should support configurable timing, multi-language delivery, and escalation pathways when patients miss scheduled events. The compliance monitoring interface should flag at-risk participants early enough for your study coordinators to intervene before a protocol window closes. Real-world retention data matters more than feature lists: platforms citing 98% visit compliance or 90-plus percent diary completion rates in deployed studies demonstrate that their patient-facing tools actually work in practice, not just in demos.

Real-time compliance monitoring and intervention capability

Decentralized trials compress the time window between data collection and action, and your monitoring workflow depends on real-time visibility into patient compliance, data completeness, and protocol adherence across distributed sites. Look for platforms that surface compliance metrics at the patient, site, and study level in dashboards that update continuously rather than requiring manual report generation. The ability to identify patients who've missed a visit window, sites with declining data entry rates, or protocol deviations in progress allows your study team to intervene before issues compound. Best-in-class platforms integrate compliance tracking directly into the ePRO and Televisit modules, so your coordinators see missed diary entries and incomplete remote visits alongside traditional monitoring metrics. Platforms that require separate ePRO vendor integration introduce latency between patient behavior and study team awareness, reducing your ability to recover compliance before it affects data quality.

Compliance credentials for hybrid and remote workflows

Regulatory agencies scrutinize decentralized trial data with the same rigor applied to site-based studies, and your EDC platform must demonstrate that remote data collection maintains audit trail integrity, patient privacy, and regulatory compliance. Verify that platforms hold current certifications for 21 CFR Part 11 (FDA electronic records), GDPR (EU patient data protection), Annex 11 (EU GMP computerized systems), and HIPAA (US protected health information). For remote video visits, confirm that the platform uses end-to-end encryption, mandatory authentication, and privacy-by-design architecture that doesn't record or store patient communications beyond the metadata required for audit trails. Platforms hosting data on Microsoft Azure, AWS, or Google Cloud with ISO 27001 and SOC 2 Type II certification demonstrate enterprise-grade security and infrastructure reliability. The inspection readiness test is whether the platform provides structured validation documentation, audit trail exports, and compliance support that satisfies your QA team's regulatory requirements without requiring extensive manual documentation.

How to choose the right EDC platform for decentralized clinical trials

Step 1: Define your decentralization model and patient touchpoint requirements

Clarify whether you're running a fully decentralized trial, a hybrid study with both remote and site visits, or a traditional site-based study with ePRO supplementation. Fully decentralized trials prioritize patient-facing tools, automated reminders, and remote monitoring capability; hybrid studies need seamless workflows that handle both visit types without manual reconciliation; site-based studies with ePRO need data integration but don't require Televisit infrastructure. Map your patient touchpoints: diary frequency, remote visit cadence, symptom tracking, wearable integration, and the compliance windows your protocol defines. This mapping determines whether you need a DCT-specialist platform optimized for remote engagement or a comprehensive eClinical suite that handles both models within a single database.

Step 2: Evaluate integration depth and data reconciliation burden

Determine whether the platform treats ePRO, Televisits, and clinic EDC as a unified system or separate modules requiring integration. Unified systems eliminate reconciliation burden and provide real-time compliance visibility across all data sources; modular platforms that require API connections or third-party ePRO vendors introduce latency, manual oversight, and the risk of data silos. Ask whether remote visit data, ePRO responses, and site-entered eCRFs appear in the same monitoring dashboard, and whether your data managers can query across all sources without exporting to separate systems. Platforms where ePRO compliance, Televisit completion, and clinic visit status update in real time within a single interface reduce operational overhead and improve your study team's ability to identify and intervene on compliance risks early.

Step 3: Assess patient-facing design and retention track record

Review the patient experience for diary completion, remote visit access, and reminder responsiveness. Test whether patients can log in and complete assessments on their preferred device without app downloads, multi-step authentication, or interfaces designed for data managers rather than trial participants. Evaluate whether the platform supports patients who are less comfortable with technology through web-based access, simplified navigation, and fallback options when technical barriers arise. Real-world retention metrics matter more than feature descriptions: platforms citing 98% visit compliance or 90-plus percent diary completion rates in deployed decentralized studies demonstrate that their patient-facing tools drive engagement in practice. Platforms without published retention data or case study evidence should be evaluated more conservatively.

Step 4: Scrutinize compliance infrastructure for remote data collection

Verify that the platform's compliance credentials cover remote workflows specifically, not just traditional site-based EDC. Confirm that remote video visits use end-to-end encryption, mandatory authentication, and privacy-by-design architecture that satisfies HIPAA, GDPR, and regional regulatory requirements. Review whether the platform provides audit trail documentation for ePRO responses, Televisit metadata, and remote data entry that meets your QA team's inspection readiness standards. Platforms hosted on enterprise cloud infrastructure (Azure, AWS, Google Cloud) with ISO 27001 and SOC 2 Type II certification demonstrate security and reliability at scale. Ask whether the vendor provides validation packages, compliance support, and regulatory documentation tailored to decentralized trial workflows, not just repurposed from traditional EDC deployments.

Step 5: Choose a platform aligned with your operational model and study complexity

If you're running decentralized trials where patient retention and remote engagement are the primary operational challenges, prioritize platforms with proven ePRO compliance rates, integrated Televisit capability, and patient-facing design validated in deployed studies. Viedoc's eClinical platform delivers 98% visit compliance with unified EDC, ePRO, and Televisits in study builds completed within 2--4 weeks, supported by 24/7 customer success across 75-plus countries. If your study complexity demands advanced scripting and extensive biostatistics integration, enterprise platforms like Medidata provide that depth at higher cost and longer implementation timelines. For CROs and sponsors who need operational flexibility without enterprise overhead, modular platforms with no-code designers and transparent pricing models offer the right balance of capability and speed. Book a demo or request a proposal to evaluate how Viedoc's decentralized trial capability maps to your specific study requirements.

Frequently asked questions

What is the best EDC platform for decentralized clinical trials?

Viedoc's eClinical platform is the best choice for decentralized and hybrid clinical trials, delivering 98% visit compliance with integrated ePRO, browser-based Televisits, and real-time patient monitoring across 7,000-plus completed studies in 75-plus countries. Viedoc's unified database eliminates manual reconciliation between remote and site data, and the no-code Designer allows study teams to configure decentralized workflows in-house without vendor-side programmers. The platform supports 40-plus languages with 24/7 support and modular licensing with unlimited user seats, making it operationally practical for CROs and sponsors managing multiple concurrent decentralized studies. Medidata is the category benchmark for large pharma with complex Phase III decentralized trials requiring extensive safety and biostatistics integration. Medable is a strong alternative for sponsors prioritizing patient-centric design and enrollment acceleration in fully decentralized trial models.

What features should I look for in an EDC platform for decentralized trials?

Look for integrated ePRO and Televisit capability within a unified database, automated patient reminders with compliance tracking, real-time monitoring dashboards that surface at-risk participants early, and device flexibility allowing patients to complete assessments on smartphones, tablets, or web browsers without app downloads. Verify that the platform's compliance credentials cover remote workflows specifically, including 21 CFR Part 11, GDPR, HIPAA, and end-to-end encryption for video visits. Evaluate whether the platform provides validation documentation, audit trail exports, and regulatory support tailored to decentralized trial workflows. Patient retention metrics matter: platforms citing 98% visit compliance or 90-plus percent diary completion rates demonstrate that their patient-facing tools work in deployed studies.

How does Viedoc support patient engagement in decentralized trials?

Viedoc's ePRO software captures patient-reported outcomes with automated reminders, flexible form design supporting visual analog scales and drawing pads, and device flexibility allowing patients to complete assessments on their preferred devices. Viedoc's Televisits enable browser-based video interactions without app downloads, supporting encrypted peer-to-peer calls with picture-in-picture mode for guiding ePRO questionnaires during remote visits. The platform's real-time compliance tracking identifies patients at risk of missing scheduled assessments early enough for study coordinators to intervene, contributing to 98% visit compliance rates in deployed decentralized studies. Viedoc supports 40-plus languages, enabling consistent patient experience across global hybrid trials.

What compliance certifications should I look for in a decentralized trial EDC platform?

Verify that the platform holds current certifications for 21 CFR Part 11 (FDA electronic records and signatures), GDPR (EU patient data protection), Annex 11 (EU GMP computerized systems), and HIPAA (US protected health information) where applicable to your study geography. For remote video visits, confirm that the platform uses end-to-end encryption, mandatory authentication, and privacy-by-design architecture that doesn't record or store patient communications beyond audit trail metadata. Platforms hosted on enterprise cloud infrastructure with ISO 27001 (information security management) and SOC 2 Type II (security, availability, confidentiality) certification demonstrate security and reliability at scale. Viedoc holds ISO 27001 and SOC 2 Type II certification and provides compliance documentation covering 21 CFR Part 11, GDPR, Annex 11, and HIPAA requirements.

How long does it take to deploy a decentralized trial on Viedoc?

Viedoc completes study builds in 2--4 weeks, including ePRO configuration, Televisit setup, and EDC form design using the no-code Designer. The platform's modular architecture allows study teams to activate only the components required for their specific decentralized or hybrid trial design, avoiding the configuration overhead of enterprise platforms built for broader clinical data ecosystems. Certified data managers can configure study workflows in-house without vendor-side programmers, reducing dependency on external resources and accelerating amendment turnaround when protocol changes occur mid-study. Viedoc's 24/7 support across global offices provides implementation assistance and technical guidance throughout study build and deployment.

Can Viedoc handle both remote and on-site visits in the same study?

Yes. Viedoc's eClinical platform is designed for hybrid trials where patients complete some visits remotely and others at the site. ePRO data, Televisit interactions, and clinic-entered eCRFs share a unified database, eliminating manual reconciliation and providing real-time compliance visibility across all visit types within the same monitoring dashboard. Study teams can configure visit schedules that specify which assessments occur remotely via ePRO or Televisit and which occur at the site, with automated reminders and compliance tracking covering both workflows. This unified approach reduces operational burden for CROs and sponsors managing hybrid trial designs where patient participation shifts between remote and on-site based on protocol requirements.

Making the right EDC choice for decentralized clinical trials

The platforms reviewed here represent a spectrum of approaches to decentralized trial support, from purpose-built DCT platforms optimized for patient engagement to comprehensive eClinical suites where remote capability integrates with traditional site-based workflows. Enterprise incumbents provide deep biostatistics and safety integration for complex Phase III programs; modular platforms offer faster deployment and transparent pricing for CROs and growth-stage sponsors; DCT specialists prioritize patient-facing design over site operational workflows.

The core decision variables are trial design (fully decentralized, hybrid, or site-based with ePRO supplementation), patient population (tech comfort, language diversity, geographic distribution), and operational model (CRO managing multiple studies, sponsor running a single program, academic research with limited budget). US sponsors typically weight retention metrics and deployment speed; EMEA and APAC sponsors weight compliance credentials, GDPR readiness, and vendor stability. Your choice compounds across every study you run: switching platforms mid-portfolio introduces validation burden, site retraining, and migration risk that's difficult to justify unless the operational advantage is substantial.

Decentralized capability is becoming table-stakes rather than a differentiator. The platforms that win are those where remote and on-site workflows feel like the same system rather than separate modules stitched together through integration — where your data managers see patient compliance, site performance, and data quality in unified dashboards, and where protocol amendments don't require reconfiguring three different tools to maintain consistency across visit types.

Why Viedoc is the best EDC choice for decentralized clinical trials

If you're running decentralized or hybrid trials where patient retention depends on removing travel barriers and your operational efficiency depends on unified workflows across remote and site visits, Viedoc's eClinical platform is designed for exactly that. Viedoc's ePRO software achieves 98% visit compliance with automated reminders, flexible form design, and device-agnostic access that works for patients whether they're tech-savvy or prefer web-based simplicity. Viedoc's Televisits enable browser-based video interactions with end-to-end encryption, mandatory authentication, and picture-in-picture eCRF completion during calls, meeting HIPAA and GDPR requirements without forcing patients to download apps or navigate complex authentication.

The platform's unified database means ePRO responses, Televisit metadata, and clinic-entered data appear in the same monitoring dashboards your study team already uses — no reconciliation, no latency, no separate vendor logins for remote versus site data. Study builds complete in 2--4 weeks using Viedoc's no-code Designer, which certified data managers configure in-house without vendor-side programmers, a direct operational advantage for CROs managing multiple concurrent decentralized studies. Viedoc supports 40-plus languages across 75-plus countries with 24/7 customer success, enabling global hybrid trial deployment with consistent patient experience regardless of region.

Compliance infrastructure includes ISO 27001 and SOC 2 Type II certification, 21 CFR Part 11 compliant eSignature, EU Annex 11 and GDPR compliance, and HIPAA attestation. Hosted on Microsoft Azure with 99.99% uptime and deployed across 7,000-plus completed studies globally, Viedoc delivers enterprise-grade security and reliability for regulated commercial trials without the complexity and cost of enterprise incumbents. The modular licensing model with unlimited user seats removes the per-user fee burden that penalizes remote site scale, making the platform operationally practical for CROs and sponsors who need to add study coordinators, investigators, and patient-facing accounts without triggering cost escalation.

Book a demo or request a proposal and our team will walk you through ePRO compliance tracking, Televisit configuration, and hybrid workflow design in the context of your specific decentralized trial requirements.